Document is current
Any future updates will be listed below
-
Authors
Pereira, Patricia Marques
Papy-Garcia, Dulce https://orcid.org/0000-0003-2225-9331
Barritault, Denis https://orcid.org/0000-0003-0315-7444
Chiappini, Franck https://orcid.org/0000-0002-2684-1241
Jackisch, Rolf
Schimchowitsch, Sarah https://orcid.org/0000-0002-2838-4523
Cassel, Jean-Christophe https://orcid.org/0000-0002-4490-9086
-
Funding
Funding for this research was provided by:
Ministère Délégué à la Recherche et aux Nouvelles Technologies (ACI NTS 2001/70)
Deutsche Forschungsgemeinschaft (Ja 244/5-2)
- License Information
-
More Information
Article History
Received: 16 August 2021
Revised: 20 December 2021
Accepted: 28 January 2022
First Online: 7 March 2022
Declarations
:
: Pr. Denis Barritault is co-inventor and co-owner in the patents describing the RGTA® technology and president of the company OTR3, manufacturer of RGTA®-based products. Dr. Franck Chiappini is an employee of OTR3. RGTA®is a registered trademark of OTR3. None of the other authors have commercial interests and they state that they have no conflict of interest.
: All animal procedures have been performed in compliance with 3R’s ethical rules on animal experimentation and in accordance with the European Directive on animal experimentation (2010/63/EU). The protocol was submitted to ethic approval of the Ministry of Higher Education and Research to obtain a project authorization for using animals for scientific purposes (Animal protocol numbers: 67-215 and 67-101 for J-CC and SS, respectively under their authorities). Every effort was made to minimize suffering, and the number of animals was as small as possible given the experimental and statistical constraints.
: The authors listed in this manuscript consented to publish this manuscript.
